Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
2026-01-30 15:37:07 ET
The last time I spoke about Perspective Therapeutics, Inc. ( CATX ), it was in a Seeking Alpha article entitled " Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept ." With respect to this article, I talked about its radiotherapeutic VMT01/02 being developed for the treatment of patients with melanoma. I also briefly mentioned that it was working on developing VMT-a-NET as a radiotherapeutic to treat patients with unresectable or metastatic somatostatin receptor type 2 [SSTR2]-positive neuroendocrine tumors [NETs] who have not received any prior radiopharmaceutical therapies [RPTs]....
Read the full article on Seeking Alpha
For further details see:
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
NASDAQ: SAN
SAN Trading
-1.85% G/L:
$10.86 Last:
7,497,165 Volume:
$11.05 Open:
